Clinical Trials Express: Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)
暂无分享,去创建一个
Sakae Tanaka | T. Sone | M. Fukunaga | T. Yoneda | H. Yoshikawa | Toshitaka Nakamura | Yoshiya Tanaka | Toshio Matsumoto | S. Matsui | T. Sugimoto | Masako Ito | M. Shiraki | T. Hosoi | I. Gorai | T. Miki | T. Nakano | H. Takami | T. Osakabe | Konosuke Watanabe | Hideo Takami
[1] S. Cummings,et al. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[2] Toshitaka Nakamura,et al. Dose–response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis , 2012, Osteoporosis International.
[3] S. Cummings,et al. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[4] Claus Christiansen,et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. , 2009, The New England journal of medicine.
[5] Jacques P. Brown,et al. Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[6] P. Miller,et al. Two‐Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[7] S. Cummings,et al. BMD at Multiple Sites and Risk of Fracture of Multiple Types: Long‐Term Results From the Study of Osteoporotic Fractures , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[8] M. Fukunaga,et al. Diagnostic criteria of primary osteoporosis , 1998, Journal of Bone and Mineral Metabolism.
[9] S. Cummings,et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.
[10] S. Cummings,et al. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis , 1996 .
[11] R. Prentice,et al. Regression analysis of grouped survival data with application to breast cancer data. , 1978, Biometrics.
[12] T. Tomomitsu,et al. Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study , 2005, Journal of Bone and Mineral Metabolism.